InterVenn Biosciences has raised $201m in a Series C funding round to develop its liquid biopsy assay and artificial intelligence (AI)-powered glycoproteomic platform.
The financing round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors and Highside Capital Management.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataInterVenn’s current investors, Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures, also took part in the round.
The company will use the funding proceeds to expedite the development and marketing of its liquid biopsy assay, Dawn, for predicting immune checkpoint inhibitor response.
Dawn is currently being developed, with commercialisation planned for next year.
The company will also grow the network of allies on its AI-driven glycoproteomics platform.
So far, the platform has been used to create 16 clinical use cases in oncology and other indications.
With favourable preliminary results and performance, InterVenn plans to fund the development of glycoproteomics-based liquid biopsy solutions in the oncology spectrum of care and non-oncology uses.
Through this funding, the company will be able to expand investment in a collaboration ecosystem to boost the development and marketing of novel clinical solutions.
Additionally, it can expand insights into new biomarkers and treatments.
InterVenn Biosciences co-founder and CEO Aldo Carrascoso said: “Our new investors, as well as our existing investors, recognise the transformative potential of our technology and bring strong industry knowledge that will result in a positive partnership for InterVenn.
“With this fundraising, we believe InterVenn is ideally positioned to unlock the glycoproteome as a novel and fundamental layer in biology, which will reveal a myriad of new insights on how to diagnose and treat disease.”
InterVenn leverages AI and mass spectrometry-driven glycoproteomics biomarker interrogation platforms for advanced precision medicine.
It focuses on developing solutions for ovarian, pancreatic, liver, prostate and kidney cancer along with solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression analysing solutions.
